This article is more than 5 years old. Information may no longer be current.
DermTech expands board of directors
Click Here to Manage Email Alerts
DermTech, a commercial stage molecular dermatology company developing non-invasive genes expression tests for clinical diagnosis in skin cancer and inflammatory skin conditions, announced that it has added Matthew Posard to its board of directors.
“Matt has over 25 years of general management and commercial experiences in the life sciences, molecular diagnostics and consumer genomics industry and has a distinguished reputation in commercializing transformative novel products and technology in the genomics space,” John Dobak, MD, DermTech CEO, stated in a press release. “We are excited to welcome him … to contribute his commercial experience to DermTech at this exciting time of commercial growth.”
Posard has held leadership roles with Illumina, Trovagene, Biosite/Alere and Gen-Probe, according to the release. He currently serves as a board member for Halozyme Therapeutics, SlipChip Corporation, Omicia and Envision Genomics.
DermTech also announced continued expansion of its commercial team with regional sales personnel, according to the release.
Reference: www.dermtech.com